61.00
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
Big Cap Pro
Monthly Subscription
for only
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
Level 1 Starter
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dr Reddys Laboratories Ltd | RDY | NYSE | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 61.00 | 19:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
61.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 61.00 | USD |
Dr Reddys Laboratories Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 10.12B | 165.92M | 165.92M | $ 2.32B | $ 361.09M | 1.56 | 59.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 48.08% | - | - |
Dr Reddys Laboratories News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RDY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 62.76 | 63.90 | 60.185 | 61.86 | 259,306 | -1.76 | -2.8% |
1 Month | 66.31 | 66.78 | 58.37 | 63.00 | 267,144 | -5.31 | -8.01% |
3 Months | 66.19 | 73.39 | 58.37 | 66.23 | 184,609 | -5.19 | -7.84% |
6 Months | 59.84 | 73.50 | 57.54 | 66.12 | 184,500 | 1.16 | 1.94% |
1 Year | 43.14 | 73.50 | 33.33 | 57.24 | 195,519 | 17.86 | 41.4% |
3 Years | 33.79 | 73.50 | 28.13 | 41.78 | 227,693 | 27.21 | 80.53% |
5 Years | 43.85 | 73.50 | 28.13 | 41.77 | 255,067 | 17.15 | 39.11% |
Dr Reddys Laboratories Description
With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, pharmaceutical services and active ingredients, and proprietary products and other, which make up most of the company's revenue at about 80%, 15%, and 3%. Most of the company's sales are based in the United States. |